Eurokem Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 1.00 M
as on 13-12-2024
- Company Age 43 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 15.40 Cr
as on 13-12-2024
- Revenue 77.44%
(FY 2022)
- Profit 190.07%
(FY 2022)
- Ebitda 124.95%
(FY 2022)
- Net Worth 69.77%
(FY 2022)
- Total Assets 54.09%
(FY 2022)
About Eurokem Laboratories
The Corporate was formerly known as Asher Pharmaceuticals P Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹15.40 Cr.
Rajesh Jain and Mahendrabjain serve as directors at the Company.
- CIN/LLPIN
U24231TN1981PTC008618
- Company No.
008618
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 1981
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Eurokem Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Jain  | Director | 28-Nov-1992 | Current |
| Mahendrabjain | Director | 28-Nov-1992 | Current |
Financial Performance of Eurokem Laboratories.
Eurokem Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 77.44% increase. The company also saw a substantial improvement in profitability, with a 190.07% increase in profit. The company's net worth Soared by an impressive increase of 69.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eurokem Laboratories?
Unlock access to Eurokem Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Chennai Pharma Industrial Infrastructure Upgradtaion CompanyActive 20 years 4 monthsRajesh Jain is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Jun 2024 | ₹7.00 Cr | Open |
Others Creation Date: 29 Dec 2018 | ₹7.50 Cr | Open |
Indian Overseas Bank Creation Date: 28 Jan 2004 | ₹9.00 M | Open |
How Many Employees Work at Eurokem Laboratories?
Eurokem Laboratories has a workforce of 47 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eurokem Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eurokem Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
